---
{"dg-publish":true,"permalink":"/human-in-loop-research/establishing-an-obesity-clinic-a-comprehensive-clinical-guide/"}
---

<script>
    // GoatCounter script
    (function() {
        var script = document.createElement('script');
        script.async = true;
        script.src = '//gc.zgo.at/count.js';
        script.setAttribute('data-goatcounter', 'https://endocrinologyindia.goatcounter.com/count');
        document.head.appendChild(script);
    })();

    // Google AdSense script
    (function() {
        var script = document.createElement('script');
        script.async = true;
        script.src = 'https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-5480881894205508';
        script.crossOrigin = 'anonymous';
        document.head.appendChild(script);
    })();
</script>

# Establishing an Obesity Clinic- A Comprehensive Clinical Guide

> [!note|+green]+ Created/Updated: #nov2025
> Research by : Google Gemini Deep Research, Perplexity Spaces & Dr. Om J Lakhani 
> Edited by: Dr. Om J Lakhani 


## INTRODUCTION

Obesity is a chronic, progressive disease affecting over 40% of adults and 19% of children in the United States [1]. Despite its high prevalence and established status as a disease, obesity remains undertreated in primary care settings, with fewer than 10% of eligible patients receiving evidence-based therapies [2]. Specialized obesity clinics can address this treatment gap by providing comprehensive care using a multidisciplinary approach.

This review provides evidence-based guidance for establishing and operating an obesity clinic, including infrastructure requirements, clinical protocols, regulatory considerations, and quality metrics. The focus is on creating a patient-centered program that delivers high-quality, comprehensive obesity care using current best practices.



## NEEDS ASSESSMENT AND PLANNING

### Epidemiologic Assessment

Before establishing an obesity clinic, a thorough needs assessment should be conducted to characterize the target population and identify service gaps. This assessment should include:

- **Local obesity prevalence and demographics**: Obesity rates vary significantly by age, race, ethnicity, and socioeconomic status [3]. Population-specific data helps tailor services to community needs.
    
- **Comorbidity patterns**: The prevalence of obesity-related comorbidities (e.g., type 2 diabetes, hypertension, sleep apnea) should be assessed to guide staffing and clinical protocols [4].
    
- **Social determinants of health**: Food insecurity, limited access to physical activity resources, and transportation barriers significantly impact obesity treatment success [5]. Understanding local social determinants helps develop appropriate interventions and support services.
    

### Competitive Analysis

A market assessment should evaluate:

- **Existing obesity services**: Identify gaps in current services, including primary care obesity management, bariatric surgery programs, and commercial weight loss programs [6].
    
- **Referral patterns**: Analyze potential referral sources, including primary care practices, endocrinology, cardiology, and sleep medicine [7].
    
- **Insurance coverage landscape**: Assess local payer mix and reimbursement policies for obesity services, which can significantly impact financial sustainability [8].
    

## CLINICAL INFRASTRUCTURE AND EQUIPMENT

### Physical Space Requirements

The clinic space should accommodate the unique needs of patients with obesity and support multidisciplinary care delivery [9,10]:

- **Waiting area**: Provide sturdy, armless chairs or couches that can accommodate patients of all sizes (minimum 450-pound capacity).
    
- **Clinical areas**: Examination rooms should be spacious enough for patients, caregivers, and multiple providers. Private weigh-in areas are essential to minimize patient distress.
    
- **Group spaces**: Dedicated areas for group education sessions and support groups enhance program offerings and efficiency.
    
- **Consultation rooms**: Private spaces for nutritional counseling and behavioral health services.
    

### Specialized Equipment

Evidence supports the importance of specialized equipment for both clinical accuracy and patient dignity [9,11]:

- **Scales**: High-capacity (minimum 600 pounds), wide-platform scales with handrails for stability. Digital scales with remote displays can enhance privacy.
    
- **Blood pressure equipment**: Various cuff sizes (regular, large adult, thigh) are essential for accurate measurement. Automated devices with various cuff options should be available.
    
- **Seating**: All clinic areas should include chairs without armrests, bariatric chairs (minimum 450-pound capacity), and seating options of varying heights.
    
- **Examination tables**: High-capacity tables (minimum 500 pounds) with step stools and support rails enhance safety and accessibility.
    
- **Anthropometric tools**: Stadiometers for height measurement and flexible, long tape measures for waist circumference.
    

### Information Technology Infrastructure

Digital infrastructure should support comprehensive obesity care [12,13]:

- **Electronic health records (EHR)**: Should include obesity-specific templates for documentation, decision support tools, and longitudinal tracking of weight and metabolic parameters.
    
- **Telemedicine capabilities**: Virtual visit platforms enhance access and enable more frequent follow-up without increasing patient burden [14].
    
- **Patient portal**: Secure messaging, appointment scheduling, and access to educational materials support patient engagement.
    
- **Data analytics**: Systems for tracking clinical outcomes, quality metrics, and practice patterns facilitate continuous quality improvement.
    

## MULTIDISCIPLINARY STAFFING

### Core Clinical Team

Evidence consistently demonstrates that multidisciplinary care improves obesity treatment outcomes compared to single-provider approaches [15,16]. The core team should include:

- **Physicians**: Ideally board-certified in obesity medicine or with specialized training in obesity management. Primary specialties may include internal medicine, family medicine, or endocrinology.
    
- **Advanced practice providers**: Nurse practitioners and physician assistants with obesity management training can enhance clinic capacity and continuity.
    
- **Registered dietitians**: Preferably with specialist certification in obesity and weight management (CSOWM) to provide medical nutrition therapy.
    
- **Behavioral health specialists**: Psychologists or licensed counselors trained in evidence-based behavioral interventions for obesity, including cognitive behavioral therapy and motivational interviewing.
    
- **Medical assistants/nurses**: Staff trained in weight-sensitive practices who can perform anthropometrics, assist with procedures, and provide basic education.
    

### Extended Team Members

Additional specialists enhance comprehensive care [16,17]:

- **Exercise physiologists**: Provide individualized physical activity prescriptions and supervised exercise programs.
    
- **Care coordinators/navigators**: Help patients navigate complex care plans and access community resources.
    
- **Pharmacists**: Consult on medication management, particularly when multiple medications are prescribed.
    
- **Social workers**: Address social determinants of health and connect patients with community resources.
    
- **Community health workers**: Enhance engagement and provide culturally sensitive support, particularly in underserved communities.
    

### Staffing Ratios and Productivity

Optimal provider-to-patient ratios depend on program intensity and patient complexity, but general guidelines suggest [18]:

- One full-time physician or advanced practice provider can manage approximately 1,500-2,000 active patients in a comprehensive obesity program.
    
- One full-time registered dietitian can support approximately 800-1,000 patients annually.
    
- One behavioral health provider can support approximately 600-800 patients annually.
    

Initial visits typically require 60 minutes with a medical provider, while follow-up visits range from 15-30 minutes depending on complexity [18].

## CLINICAL PROGRAM DESIGN

### Patient Evaluation Protocol

Comprehensive initial evaluation should include [19,20]:

- **Obesity-specific history**: Assessment of weight trajectory, previous weight loss attempts, weight-related health concerns, and readiness for change.
    
- **Medical history**: Focused on obesity-related comorbidities and conditions that may impact treatment options.
    
- **Physical examination**: Comprehensive assessment including vital signs, anthropometrics (height, weight, BMI, waist circumference), and evaluation for obesity-related physical findings.
    
- **Laboratory evaluation**: Typically includes comprehensive metabolic panel, lipid profile, hemoglobin A1C, thyroid function tests, and other tests as clinically indicated.
    
- **Screening for disordered eating**: Using validated tools such as the Binge Eating Scale or Eating Disorder Examination Questionnaire.
    
- **Quality of life assessment**: Using validated instruments such as the Impact of Weight on Quality of Life (IWQOL-Lite) or Short Form-36 (SF-36).
    

### Treatment Planning

Evidence-based, personalized treatment plans should include [21,22]:

- **Weight management goals**: Typically 5-15% weight loss over 6-12 months, with emphasis on health improvements rather than specific weight targets.
    
- **Nutritional intervention**: Individualized dietary approaches based on patient preferences, cultural considerations, and comorbidities.
    
- **Physical activity prescription**: Structured program starting at current activity level with gradual progression toward 150-300 minutes per week of moderate-intensity activity.
    
- **Behavioral therapy**: Cognitive-behavioral approaches including self-monitoring, stimulus control, and problem-solving strategies.
    
- **Pharmacotherapy**: FDA-approved anti-obesity medications for eligible patients (BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities).
    
- **Medical device consideration**: For appropriate candidates (e.g., intragastric balloons).
    
- **Surgical referral**: For patients meeting criteria for bariatric surgery.
    

### Intervention Intensity and Follow-up

Treatment intensity significantly impacts outcomes, with more intensive interventions yielding greater weight loss [23,24]:

- **High-intensity programs** (≥14 sessions in 6 months) produce mean weight losses of 5-8% of initial weight.
    
- **Moderate-intensity programs** (6-13 sessions in 6 months) typically yield 4-5% weight loss.
    
- **Low-intensity programs** (<6 sessions in 6 months) generally produce <3% weight loss.
    

Recommended follow-up frequency [19,21]:

- **Initial phase** (months 1-3): Biweekly to weekly visits
- **Intensive intervention phase** (months 3-6): Every 2-4 weeks
- **Maintenance phase** (beyond 6 months): Monthly to quarterly visits

### Group-Based Interventions

Group programs enhance clinical efficiency and leverage social support [25,26]:

- **Shared medical appointments**: Combine individual medical assessment with group education and support, typically 90-120 minutes with 8-12 patients.
    
- **Structured behavioral programs**: Evidence-based curriculums such as the Diabetes Prevention Program (DPP) or commercially available programs with documented efficacy.
    
- **Support groups**: Facilitated peer support enhances long-term engagement and maintenance.
    

## PHARMACOTHERAPY PROTOCOLS

### Medication Selection Guidelines

Anti-obesity medication prescribing should follow a structured approach [27,28]:

- **Patient selection**: Appropriate for adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity.
    
- **Medication choice**: Should be individualized based on:
    
- Comorbidities and potential therapeutic benefits
    
- Contraindications and safety considerations
    
- Cost and insurance coverage
    
- Patient preferences
    
- **FDA-approved medications**: Current options include orlistat, phentermine, phentermine-topiramate ER, naltrexone-bupropion ER, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide 5-15 mg [29].
    

### Medication Monitoring Protocols

Standardized monitoring enhances safety and effectiveness [27,30]:

- **Baseline evaluation**: Comprehensive metabolic panel, lipid profile, hemoglobin A1C, and medication-specific testing before initiation.
    
- **Follow-up assessments**: Regular monitoring of weight, blood pressure, heart rate, and medication-specific parameters.
    
- **Efficacy benchmarks**: Evaluate for ≥5% weight loss from baseline at 3 months (or medication-specific timeframe). Consider dose adjustment, addition of adjunctive therapy, or medication change if inadequate response.
    
- **Adverse effect management**: Structured protocols for common side effects to improve adherence and outcomes.
    
- **Long-term use**: Current evidence supports continued use of anti-obesity medications for chronic management, with regular reassessment of benefit-risk profile [31].
    

## QUALITY IMPROVEMENT AND OUTCOMES TRACKING

### Clinical Outcome Metrics

Standardized outcome measures facilitate quality improvement and program evaluation [32,33]:

- **Weight outcomes**:
    
- Percentage of patients achieving ≥5% weight loss at 6 months and 1 year
    
- Percentage of patients achieving ≥10% weight loss at 1 year
    
- Mean percentage weight change across the practice
    
- Weight regain rates during maintenance phase
    
- **Cardiometabolic outcomes**:
    
- Changes in blood pressure, lipids, and glycemic control
    
- Medication reduction/discontinuation for obesity-related conditions
    
- **Functional outcomes**:
    
- Physical activity levels
    
- Quality of life scores using validated instruments
    
- Mobility and activities of daily living
    
- **Patient-reported outcomes**:
    
- Treatment satisfaction
    
- Eating behaviors
    
- Weight-related quality of life
    

### Process Metrics

Process measures help identify operational improvement opportunities [32,34]:

- **Access metrics**: New appointment wait times, visit completion rates
- **Utilization patterns**: Visit frequency, multidisciplinary service utilization
- **Retention rates**: Percentage of patients continuing in care at 3, 6, and 12 months
- **Medication management**: Appropriate prescribing and monitoring rates
- **Comorbidity screening**: Rates of appropriate screening for obesity-related conditions

### Quality Improvement Framework

A structured approach to quality improvement enhances program effectiveness [35]:

- **Regular data review**: Monthly or quarterly review of key metrics by the multidisciplinary team.
    
- **Plan-Do-Study-Act (PDSA) cycles**: Implement small tests of change to address identified improvement opportunities.
    
- **Benchmarking**: Compare outcomes to published standards and other obesity programs.
    
- **Patient advisory input**: Include patient perspectives in program evaluation and improvement efforts.
    

## REGULATORY AND LEGAL CONSIDERATIONS

### Licensing and Credentialing

Obesity clinics must address several regulatory requirements [36,37]:

- **Facility licensure**: Requirements vary by state and practice setting (hospital-based vs. independent).
    
- **Provider credentialing**: Verification of appropriate training and certification, particularly for prescribing controlled substances.
    
- **Special certifications**: Some states have specific requirements for prescribing weight loss medications or operating weight management programs.
    

### Documentation and Coding Guidelines

Proper documentation enhances reimbursement and legal protection [38,39]:

- **Obesity diagnosis**: Document using appropriate ICD-10 codes (E66.01, E66.09, E66.1, E66.2, E66.8, E66.9) with specificity.
    
- **Comorbidity documentation**: Clearly establish relationships between obesity and comorbid conditions.
    
- **Medical necessity**: Document how obesity treatment addresses specific health conditions and previous treatment attempts.
    
- **Service documentation**: Specify time spent, interventions provided, and multidisciplinary components.
    

### Compliance Considerations

Obesity clinics must adhere to various regulations [36,40]:

- **HIPAA compliance**: Ensure privacy and security of patient information.
    
- **Anti-kickback regulations**: Particularly relevant for relationships with device manufacturers, pharmaceutical companies, or bariatric surgery programs.
    
- **Controlled substance regulations**: Adhere to DEA requirements for prescribing phentermine and other controlled medications.
    
- **Advertising guidelines**: Marketing materials must comply with FTC regulations regarding claims and disclosures.
    

## FINANCIAL SUSTAINABILITY

### Reimbursement Landscape

Understanding the reimbursement environment is critical for sustainability [41,42]:

- **Medicare coverage**: Intensive behavioral therapy for obesity is covered when provided by primary care practitioners in primary care settings. Limited medication coverage.
    
- **Medicaid coverage**: Varies significantly by state, with increasing coverage for obesity treatments.
    
- **Commercial insurance**: Coverage varies widely, with growing coverage for behavioral therapy, medications, and surgery.
    
- **Self-pay considerations**: Transparent pricing and package options enhance accessibility for uninsured or underinsured patients.
    

### Revenue Cycle Optimization

Effective financial management strategies include [41,43]:

- **Accurate coding**: Use appropriate CPT codes for evaluation and management services, preventive services, nutrition therapy, behavioral counseling, and care coordination.
    
- **Prior authorization processes**: Streamlined protocols for medication and procedure approvals.
    
- **Insurance verification**: Systematic pre-visit benefits verification for obesity services.
    
- **Alternative payment models**: Consider value-based contracts based on weight loss outcomes or comorbidity improvement.
    

## SUMMARY AND RECOMMENDATIONS

Establishing a successful obesity clinic requires thoughtful planning, comprehensive infrastructure, and evidence-based clinical protocols. Based on current evidence, we recommend:

- **Perform a thorough needs assessment** before clinic launch to tailor services to local population needs and healthcare landscape. (Grade 2B)
    
- **Invest in obesity-specific equipment and facilities** that accommodate patients with obesity safely and respectfully. (Grade 1B)
    
- **Implement a multidisciplinary care model** including medical, nutritional, behavioral, and exercise components for optimal outcomes. (Grade 1A)
    
- **Develop structured clinical protocols** for comprehensive assessment, personalized treatment planning, and regular monitoring. (Grade 1B)
    
- **Offer high-intensity intervention programs** (≥14 sessions in 6 months) to maximize weight loss outcomes. (Grade 1A)
    
- **Incorporate anti-obesity medications** for eligible patients as part of comprehensive treatment. (Grade 1A)
    
- **Implement systematic outcomes tracking** using standardized metrics to facilitate quality improvement. (Grade 2B)
    
- **Ensure compliance with regulatory requirements** for facility operation, provider credentialing, and controlled substance prescribing. (Grade 1C)
    
- **Develop a sustainable financial model** with diverse revenue streams and efficient revenue cycle management. (Grade 2C)
    

The field of obesity medicine continues to evolve rapidly, with emerging medications, technologies, and care models. Ongoing professional education, quality improvement initiatives, and adaptation to changing evidence are essential for maintaining a state-of-the-art obesity clinic.

## REFERENCES

1. Centers for Disease Control and Prevention. Adult Obesity Facts. Updated 2022. Accessed January 2023. [https://www.cdc.gov/obesity/data/adult.html](https://www.cdc.gov/obesity/data/adult.html)
    
2. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national ACTION study. Obesity. 2018;26(1):61-69.
    
3. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;(360):1-8.
    
4. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.
    
5. Hill JO, Galloway JM, Goley A, et al. Socioecological determinants of prediabetes and type 2 diabetes. Diabetes Care. 2013;36(8):2430-2439.
    
6. AMGA Foundation. Obesity Care Model. 2023. Available from: [https://www.amga.org/performance-improvement/best-practices/collaborative-programs/obesity-care-model/](https://www.amga.org/performance-improvement/best-practices/collaborative-programs/obesity-care-model/)
    
7. Wadden TA, Tsai AG, Tronieri JS. A protocol to deliver intensive behavioral therapy (IBT) for obesity in primary care settings: the MODEL-IBT program. Obesity. 2019;27(10):1562-1566.
    
8. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450.
    
9. Camden SG. Obesity: an emerging concern for patients and providers. Nurse Pract. 2009;34(12):36-42.
    
10. Brown I, Thompson J. Primary care nurses' attitudes, beliefs and own body size in relation to obesity management. J Adv Nurs. 2007;60(5):535-543.
    
11. Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015;16(4):319-326.
    
12. Eaton CB, Hartman SJ, Perzanowski E, et al. A randomized clinical trial of a tailored lifestyle intervention for obese, sedentary, primary care patients. Ann Fam Med. 2016;14(4):311-319.
    
13. Thomas JG, Bond DS, Raynor HA, Papandonatos GD, Wing RR. Comparison of smartphone-based behavioral obesity treatment with standard dietary counseling: a randomized controlled trial. J Med Internet Res. 2019;21(10):e14726.
    
14. Kozak AT, Buscemi J, Hawkins MAW, et al. Technology-based interventions for weight management: current randomized controlled trial evidence and future directions. J Behav Med. 2017;40(1):99-111.
    
15. Tsai AG, Wadden TA. Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med. 2009;24(9):1073-1079.
    
16. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA. 2014;312(17):1779-1791.
    
17. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-S138.
    
18. Welzel FD, Stein J, Pabst A, et al. Five A's counseling in weight management of obese patients in primary care: a cluster-randomized controlled trial (INTERACT). BMC Fam Pract. 2018;19(1):97.
    
19. Kushner RF, Ryan DH. Assessment and lifestyle management of patients with obesity: clinical recommendations from systematic reviews. JAMA. 2014;312(9):943-952.
    
20. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
    
21. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(11):1172-1191.
    
22. Kahan S, Zvenyach T. Obesity as a disease: current policies and implications for the future. Curr Obes Rep. 2016;5(2):291-297.
    
23. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology. 2007;132(6):2226-2238.
    
24. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-1686.
    
25. Paul-Ebhohimhen V, Avenell A. A systematic review of the effectiveness of group versus individual treatments for adult obesity. Obes Facts. 2009;2(1):17-24.
    
26. Befort CA, Donnelly JE, Sullivan DK, Ellerbeck EF, Perri MG. Group versus individual phone-based obesity treatment for rural women. Eat Behav. 2010;11(1):11-17.
    
27. Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin North Am. 2018;102(1):135-148.
    
28. Bray GA, Frühbeck G, Ryan DH, Wilding JP. Management of obesity. Lancet. 2016;387(10031):1947-1956.
    
29. Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009-2015. Obesity. 2019;27(12):1975-1981.
    
30. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74-86.
    
31. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730.
    
32. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.
    
33. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014;22(1):5-13.
    
34. Hamdy O, Mottalib A, Morsi A, et al. Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study. BMJ Open Diabetes Res Care. 2017;5(1):e000259.
    
35. Kramer MK, Molenaar DM, Arena VC, et al. Improving employee health: evaluation of a worksite lifestyle change program to decrease risk factors for diabetes and cardiovascular disease. J Occup Environ Med. 2015;57(3):284-291.
    
36. Dietz WH, Baur LA, Hall K, et al. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015;385(9986):2521-2533.
    
37. Tsai AG, Remmert JE, Butryn ML, Wadden TA. Treatment of obesity in primary care. Med Clin North Am. 2018;102(1):35-47.
    
38. Kushner RF. Clinical assessment and management of adult obesity. Circulation. 2012;126(24):2870-2877.
    
39. Bleich SN, Bennett WL, Gudzune KA, Cooper LA. National survey of US primary care physicians' perspectives about causes of obesity and solutions to improve care. BMJ Open. 2012;2(6):e001871.
    
40. Gudzune KA, Bennett WL, Cooper LA, Bleich SN. Perceived judgment about weight can negatively influence weight loss: a cross-sectional study of overweight and obese patients. Prev Med. 2014;62:103-107.
    
41. Jannah N, Hild J, Gallagher C, Dietz W. Coverage for obesity prevention and treatment services: analysis of Medicaid and state employee health insurance programs. Obesity. 2018;26(12):1834-1840.
    
42. Kyle TK, Stanford FC, Nadglowski J, Hainer V. Financial implications of covering obesity services for commercial health plans, employers, and patients. Endocr Pract. 2022;28(2):219-226.
    
43. Yang YT, Pomeranz JL, Burger AE. The commercial marketing of healthy lifestyles to address the global child and adolescent obesity pandemic: prospects, pitfalls and priorities. Public Health. 2017;153:79-87.
